Pre-clinical and translational pharmacology of a human interleukin-22 IgG fusion protein for potential treatment of infectious or inflammatory diseases
- 1 June 2018
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 152, 224-235
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Strategies for extended serum half-life of protein therapeuticsCurrent Opinion in Biotechnology, 2011
- Regulation and Functions of the IL-10 Family of Cytokines in Inflammation and DiseaseAnnual Review of Immunology, 2011
- Projecting human pharmacokinetics of therapeutic antibodies from nonclinical datamAbs, 2011
- CD4+ Lymphoid Tissue-Inducer Cells Promote Innate Immunity in the GutImmunity, 2011
- Activation of epithelial STAT3 regulates intestinal homeostasisCell Cycle, 2010
- STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healingJournal of Experimental Medicine, 2009
- IL-22 Increases the Innate Immunity of TissuesImmunity, 2004
- Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activationHepatology, 2004
- Identification of the Functional Interleukin-22 (IL-22) Receptor ComplexJournal of Biological Chemistry, 2001
- Animal scale-upJournal of Pharmacokinetics and Biopharmaceutics, 1973